The University of Oklahoma Health Campus anchors Project 200’s commitment to improving health outcomes through discovery, translation, and precision medicine at scale. Oklahoma’s high burden of chronic disease, health disparities, and rural and underserved populations create both urgency and opportunity, positioning OU as one of the most consequential places in the nation to advance precision medicine, prevention, and new models of care. By recruiting nationally competitive research leaders and teams, OU will build integrated, disease-focused research engines that move seamlessly from molecular discovery to clinical trials, health systems implementation, and population-level impact.
The Stephenson Cancer Center is already changing healthcare outcomes for Oklahomans right at home. Expanding this research ecosystem with a focus on reducing incidence, improving early detection, and delivering more effective, personalized therapies for cancers that disproportionately affect Oklahomans, will give more and more Oklahomans the strongest possible fighting chance against cancer, no matter where they live in the state.
OU’s diabetes efforts have a core mission in understanding, preventing and treating diabetes and metabolic disease, some of the most pressing and costly health challenges facing Oklahomans and the nation. Through the Harold Hamm Diabetes Center OU will advance solutions to reduce disease burden and improve long-term outcomes.
Through a new Neuroscience Institute and Initiative, OU will advance discovery and translation across the full spectrum of brain health, addressing neurological and psychiatric conditions that profoundly affect quality of life, productivity, and health equity.
OU will lead in identifying and addressing the biological, social, environmental, and systemic drivers of chronic disease and bridge precision medicine with public health to improve outcomes at population scale.
OU will expand its capacity to rapidly translate discovery into patient benefit by building an integrated, next-generation clinical trials and translational research ecosystem. Key to this initiative is the creation of an integrated Clinical Trials Office and recruitment of investigators focused on Clinical Trials.
.jpg)
OU will expand across the Health Campus in additional priority areas aligned with the strategic plans of each of the colleges (Allied Health, Dentistry, Graduate, Medicine, Nursing, Pharmacy, Public Health)
Cross-campus initiatives at OU unite biomedical data science and AI, molecular and cellular biology, and engineering to accelerate discovery, enable precision healthcare, and develop next-generation diagnostics, therapies, and technologies for all Oklahomans.
A powerful new $16 million cyclotron is arriving soon at the University of Oklahoma College of Pharmacy, marking a major expansion of advanced medical imaging, cancer treatment and research capabilities for patients across the state.
A $1.7 million grant from the National Institutes of Health will allow a University of Oklahoma researcher to continue investigating a protein that may help explain why Lupus develops and how it might be treated more precisely.
The University of Oklahoma Health Campus was recently recognized for its increased momentum in advancing discoveries that change lives, achieving the state’s first Top 100 national ranking based on funding from the National Institutes of Health, according to the Blue Ridge Institute for Medical Research. The ranking—the highest in OU’s history and in the state—solidifies the University’s position as the state’s leading driver of health-related research.
University of Oklahoma researchers have created a new drug delivery system that helps cancer cells take in much more of a treatment, improving its ability to kill tumors. “The delivery system is like a Trojan horse,” said Joshua Seaberg, Ph.D., the doctoral student who created the system.
A team from OU and WVU recently earned a five-year, $3.5 million grant from the National Institutes of Health to study how concept cigarillos influence the potential for addiction. The results will be used to inform the FDA’s impending flavor ban on cigar products and could have wider-reaching implications for other tobacco products that come in flavors, such as e-cigarettes and tobacco-free nicotine pouches.
Results of a Phase III clinical trial published recently in The Lancet show that oropharyngeal cancer patients receiving proton therapy kept their cancer under control just as well as patients receiving traditional radiation therapy, or photon therapy, and that they were more likely to be alive at the five-year mark of the study and suffered fewer side effects.
The Oklahoma Tobacco Settlement Endowment Trust (TSET) has awarded the University of Oklahoma a $25 million grant to help construct a new OU Health Stephenson Cancer Center facility in Tulsa, a project that will house the newly named TSET Clinical Research Center and significantly expand access to clinical trials and cancer care in the region.
A new study from the University of Oklahoma suggests that small genetic differences in two proteins – previously known for their role in premature infants’ lungs – may also influence how their eyes develop, potentially affecting the risk of retinopathy of prematurity (ROP).
University of Oklahoma researcher Elizabeth Wellberg, Ph.D., is the senior author of a review article in The Journal of Clinical Investigation that gathers current research evidence about the effects of GLP-1 drugs, like Ozempic and Zepbound, on cancer risk.
As part of their mission to expand access to oral health care across Oklahoma, the University of Oklahoma College of Dentistry and the Oklahoma Dental Foundation (ODF) have launched a mobile dental clinic in Guymon, offering services for patients of all ages. The clinic, a key program of ODF, is stationed in the parking area of Memorial Hospital of Texas County.
